Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
Background: Colorectal cancer (CRC) with lung metastases has an unfavorable prognosis. However, nowadays, even advanced CRC can have a favorable outcome in certain cases. A complete response (CR) is a rare event in advanced CRC with lung metastases. Herein, we report 2 rare cases of advanced CRC att...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2018-08-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/492568 |
| _version_ | 1818508281856917504 |
|---|---|
| author | Yuta Ushida Eiji Shinozaki Keisho Chin Mitsukuni Suenaga Daisuke Takahari Masato Ozaka Mariko Ogura Takashi Ichimura Takeru Wakatsuki Kensei Yamaguchi |
| author_facet | Yuta Ushida Eiji Shinozaki Keisho Chin Mitsukuni Suenaga Daisuke Takahari Masato Ozaka Mariko Ogura Takashi Ichimura Takeru Wakatsuki Kensei Yamaguchi |
| author_sort | Yuta Ushida |
| collection | DOAJ |
| description | Background: Colorectal cancer (CRC) with lung metastases has an unfavorable prognosis. However, nowadays, even advanced CRC can have a favorable outcome in certain cases. A complete response (CR) is a rare event in advanced CRC with lung metastases. Herein, we report 2 rare cases of advanced CRC attaining a CR. Case Presentation: Case 1 was a 58-year-old man who underwent laparoscopic ileocecal resection for cecum cancer with multiple metastases to the lungs in 2011. We performed treatment with mFOLFOX6 and bevacizumab chemotherapy in August 2011. After 11 courses, computed tomography (CT) revealed a CR to chemotherapy in February 2012. He has remained disease-free for 5 years and 3 months. Case 2 was a 70-year-old woman who underwent laparoscopic ileocecal resection for cecum cancer in August 2010. Recurrence of multiple metastases to both lungs was detected in November 2010. We started treatment with XELOX and bevacizumab chemotherapy in January 2011. In January 2011, CT after 14 courses revealed disappearance of the lung lesions, thereby indicating a CR. She has remained disease-free for 5 years and 4 months. Conclusion: We encountered 2 patients with CRC with lung metastases who were treated with chemotherapy leading to a CR. Cases resulting in such a desirable outcome are extremely rare. |
| first_indexed | 2024-12-10T22:29:29Z |
| format | Article |
| id | doaj.art-de2e4de53b094e818ba71695fdf17ada |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-10T22:29:29Z |
| publishDate | 2018-08-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-de2e4de53b094e818ba71695fdf17ada2022-12-22T01:31:05ZengKarger PublishersCase Reports in Oncology1662-65752018-08-0111260160810.1159/000492568492568Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + BevacizumabYuta UshidaEiji ShinozakiKeisho ChinMitsukuni SuenagaDaisuke TakahariMasato OzakaMariko OguraTakashi IchimuraTakeru WakatsukiKensei YamaguchiBackground: Colorectal cancer (CRC) with lung metastases has an unfavorable prognosis. However, nowadays, even advanced CRC can have a favorable outcome in certain cases. A complete response (CR) is a rare event in advanced CRC with lung metastases. Herein, we report 2 rare cases of advanced CRC attaining a CR. Case Presentation: Case 1 was a 58-year-old man who underwent laparoscopic ileocecal resection for cecum cancer with multiple metastases to the lungs in 2011. We performed treatment with mFOLFOX6 and bevacizumab chemotherapy in August 2011. After 11 courses, computed tomography (CT) revealed a CR to chemotherapy in February 2012. He has remained disease-free for 5 years and 3 months. Case 2 was a 70-year-old woman who underwent laparoscopic ileocecal resection for cecum cancer in August 2010. Recurrence of multiple metastases to both lungs was detected in November 2010. We started treatment with XELOX and bevacizumab chemotherapy in January 2011. In January 2011, CT after 14 courses revealed disappearance of the lung lesions, thereby indicating a CR. She has remained disease-free for 5 years and 4 months. Conclusion: We encountered 2 patients with CRC with lung metastases who were treated with chemotherapy leading to a CR. Cases resulting in such a desirable outcome are extremely rare.https://www.karger.com/Article/FullText/492568Colorectal cancerComplete responseLong-term survivalBevacizumabLung metastasis |
| spellingShingle | Yuta Ushida Eiji Shinozaki Keisho Chin Mitsukuni Suenaga Daisuke Takahari Masato Ozaka Mariko Ogura Takashi Ichimura Takeru Wakatsuki Kensei Yamaguchi Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab Case Reports in Oncology Colorectal cancer Complete response Long-term survival Bevacizumab Lung metastasis |
| title | Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab |
| title_full | Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab |
| title_fullStr | Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab |
| title_full_unstemmed | Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab |
| title_short | Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab |
| title_sort | two cases of long term survival of advanced colorectal cancer with synchronous lung metastases treated with mfolfox6 xelox bevacizumab |
| topic | Colorectal cancer Complete response Long-term survival Bevacizumab Lung metastasis |
| url | https://www.karger.com/Article/FullText/492568 |
| work_keys_str_mv | AT yutaushida twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT eijishinozaki twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT keishochin twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT mitsukunisuenaga twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT daisuketakahari twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT masatoozaka twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT marikoogura twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT takashiichimura twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT takeruwakatsuki twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab AT kenseiyamaguchi twocasesoflongtermsurvivalofadvancedcolorectalcancerwithsynchronouslungmetastasestreatedwithmfolfox6xeloxbevacizumab |